References
Dahlöf B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.
Lindholm LH, Ibsen H, Borch-Johnsen K, et al., for the LIFE Study Group: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20:1879–1886.
Lindholm LH, Ibsen H, Dahlöf B, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.
Kjeldsen SE, Dahlöf B, Deverux RB, et al., for the LIFE Study Group: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002, 288:1491–1498.
Lithell H, Hansson L, Skoog I, et al., for the SCOPE study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): prinicipal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875–886.
Mann J, Julius S, for the VALUE Trial Group: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998, 7:176–183.
Kjeldsen SE, Julius S, Brunner H, et al., for the VALUE Trial Group: Characteristics of 15314 hypertensive patients at high coronary risk: the VALUE trial. Blood Press 2001, 10:83–91.
Julius S, Kjeldsen SE, Weber M, et al., for the VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.
Weber M, Julius S, Kjeldsen SE, for the VALUE Trial Group: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049–2051.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kjeldsen, S.E., Westheim, A.S. & Os, I. Prevention of cardiovascular events and diabetes with angiotensin-receptor blockers in hypertension: Life, scope, and value. Current Science Inc 7, 155–157 (2005). https://doi.org/10.1007/s11906-005-0001-8
Issue Date:
DOI: https://doi.org/10.1007/s11906-005-0001-8